Table of contents
In this issue
p939 | doi:10.1038/nrd2484
Editorial: Three decades of antiviral drugs
p941 | doi:10.1038/nrd2485
News and Analysis
Bad bugs need more drugs | PDF (742 KB)
p943 | doi:10.1038/nrd2477
Novel risk-sharing scheme puts the spotlight on biomarkers | PDF (247 KB)
p945 | doi:10.1038/nrd2478
News in Brief
Patent watch
US patent office changes halted | UK patent ownership redefined | Roche infringes Amgen's erythropoietin patents | Antiviral actions of interferons | PDF (292 KB)
p948 | doi:10.1038/nrd2480
An Audience With
Tadataka Yamada | PDF (135 KB)
p950 | doi:10.1038/nrd2481
From the analyst's couch
HIV combination products | PDF (431 KB)
p951 | doi:10.1038/nrd2448
Fresh from the Pipeline
Ixabepilone | PDF (239 KB)
p953 | doi:10.1038/nrd2469
Research Highlights
Antivirals: Mirror image inhibition | PDF (141 KB)
p955 | doi:10.1038/nrd2474
Drug development: Predicting toxicity | PDF (303 KB)
p956 | doi:10.1038/nrd2470
Informatics: The ABCD of data management | PDF (222 KB)
p956 | doi:10.1038/nrd2471
Antivirals: MicroRNA versus virus: uncovering new layers of complexity | PDF (364 KB)
p957 | doi:10.1038/nrd2472
Immunomodulators: Enhancing regulation | PDF (309 KB)
p958 | doi:10.1038/nrd2473
In brief
Gene silencing | Hyperlipidaemic disease | Neurodegenerative disease | Biotechnology | PDF (180 KB)
p958 | doi:10.1038/nrd2475
Focus on: Antivirals
Perspectives
Timeline
HIV drug development: the next 25 years
Charles Flexner
p959 | doi:10.1038/nrd2336
HIV has been the most active field of antiviral drug research and development since the discovery of the virus a quarter of a century ago. Flexner provides an overview of current opportunities and novel targets in HIV drug discovery, and analyses the central questions pertinent for the next 25 years of drug development for HIV.
Article series: Case Histories
Case history
The war against influenza: discovery and development of sialidase inhibitors
Mark von Itzstein
p967 | doi:10.1038/nrd2400
The threat of an influenza pandemic has heightened the need for therapeutic strategies to combat this virus. This article provides a historical perspective on the discovery and development of two drugs that are at the forefront of our defences against influenza — the sialdiase inhibitors zanamivir and oseltamivir — highlighting the value of structure-based drug design in this process.
Reviews
Interferons at age 50: past, current and future impact on biomedicine
Ernest C. Borden, Ganes C. Sen, Gilles Uze, Robert H. Silverman, Richard M. Ransohoff, Graham R. Foster & George R. Stark
p975 | doi:10.1038/nrd2422
Interferons (IFNs) provide fundamental cellular defence mechanisms against viral infections and cancer. On the 50th anniversary of the discovery of IFNs, the authors provide a comprehensive overview of IFN biology, human therapeutic applications and potential drug targets within the IFN system.
The way forward in HCV treatment — finding the right path
Michael P. Manns, Graham R. Foster, Jürgen K. Rockstroh, Stefan Zeuzem, Fabien Zoulim & Michael Houghton
p991 | doi:10.1038/nrd2411
Insights into the life cycle of hepatitis C virus (HCV) have facilitated the development of a number of innovative agents. Here, Manns and colleagues discuss the obstacles in current HCV management, the key challenges for new HCV antivirals and potential future therapeutic options.
The design of drugs for HIV and HCV
Erik De Clercq
p1001 | doi:10.1038/nrd2424
Drug development for HIV has been the major driving force in antiviral research. The strategies that are now being pursued for combating hepatitis C virus (HCV) are remarkably reminiscent of those established for HIV. Here, De Clercq reviews aspects of the medicinal chemistry and history of drug design for HIV and HCV.
